MetaCap

Clene (CLNN) vs Heron Therapeutics (HRTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Clene (CLNN) has outperformed Heron Therapeutics (HRTX) over the past year, losing 62.0% versus a loss of 76.2%. Over five years, CLNN leads with a -96.3% price change compared with -97.3% for HRTX. Clene is the larger company by market cap ($50.7 million vs $48.0 million), about 1.1 times the size, while Heron Therapeutics is growing revenue faster (+7.4% vs -41.5%).

Heron Therapeutics converts more of its revenue into profit, with a net margin of -13.0% versus -13086.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CLNN-62.03%HRTX-76.18%
+46%-18%-82%
Nov 21, 20251 yearNov 20, 2026
CLNN-96.51%HRTX-97.51%
+10%-46%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CLNN versus HRTX key metrics
MetricCLNNHRTX
Share price$3.52$0.2525
Market cap$50.69M$48.04M
1-day change+0.57%-4.39%
YTD return-40.03%-80.58%
1-year return-62.03%-76.18%
5-year return-96.28%-97.32%
EPS (TTM)$-2.30$-0.11
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$200.00K$154.90M
Revenue growth (YoY)-41.52%+7.36%
Net income (latest FY)$-26.17M$-20.20M
Gross margin78.50%73.31%
Operating margin-11541.50%-1.64%
Net margin-13086.50%-13.04%
52-week high$10.84$1.58
52-week low$3.02$0.2479
Distance from 52-week high-67.53%-84.02%
Analyst consensusnonenone
Avg. price target upside+814.77%+2672.28%
Average volume115.06K4.56M
Shares outstanding14.40M190.27M
Employees76128
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CLNN has outperformed HRTX by 14.2 percentage points over the past year.
  • Heron Therapeutics is more profitable, keeping -13.0 cents of every revenue dollar as net income versus -13086.5 cents for Clene.
  • Heron Therapeutics grew revenue faster in its latest fiscal year (+7.36% vs -41.52%).

About Clene

CLNN stock →

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

About Heron Therapeutics

HRTX stock →

Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.

Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees

CLNN vs HRTX FAQ

Which is bigger, Clene or Heron Therapeutics?

Clene (CLNN) is larger, with a market capitalization of $50.69M compared with $48.04M for Heron Therapeutics (HRTX).

Which stock has performed better over the past year, CLNN or HRTX?

CLNN returned -62.03% over the past 12 months, compared with -76.18% for HRTX (price return, excluding dividends). Past performance does not predict future results.

Are Clene and Heron Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons